Ketek (Telithromycin) highly active in vitro against Streptococcus pneumoniae

A novel investigational antibiotic has demonstrated excellent in vitro activity against isolates of Streptococcus pneumoniae (S. pneumoniae), including those resistant to penicillin, macrolide or fluoroquinolone antibiotics according to a study presented today. In vitro data from the international PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) study presented today at the 11th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), suggest that Ketek (telithromycin) may be an effective option for the treatment of community acquired respiratory tract infections (CARTIs), particularly those caused by Streptococcus pneumoniae, the most common pathogen associated with CARTIs.

CARTIs are the most common infections treated by healthcare practitioners and represent a significant societal burden, causing 50 million deaths globally each year. As part of the worldwide PROTEKT study, bacterial isolates from patients with community-acquired pneumonia (CAP), acute bacterial exacerbation of chronic bronchitis (AECB), acute sinusitis, tonsillitis/pharyngitis or acute otitis media were collected from centres throughout the world. As of January 2001, the in vitro analysis of more than 5000 isolates collected in the PROTEKT study has confirmed the alarming spread of antimicrobial resistance among the pathogens most frequently implicated in CARTIs.

The study revealed that the overall worldwide prevalence of penicillin (PEN) resistance among pneumococci was 39.9%. Levels differed markedly among countries with South Korea recording the highest levels (80.5%). High levels of PEN resistance were also evident in Japan (65.6%), Hong Kong (58.6%), France (59.4%), Spain (43.7%) and the USA (43.6%).

The study also shows that erythromycin (ERY) resistance was highest in Asia (combined ERY resistance of 86.2%, 80.5% and 72.9% in South Korea, Japan and Hong Kong, respectively), and more than half of

Contact: Liz Rickard

Page: 1 2 3

Related biology news :

1. Ketek receives marketing approval in Europe
2. Ketek effective against respiratory tract infections with reduced susceptibility to other antibiotics
3. Byproduct of water-disinfection process found to be highly toxic
4. NIST study shows computerized fingerprint matching is highly accurate
5. Asian bird flu became highly pathogenic through continued circulation and gene swapping
6. New compound highly efficacious at reducing human tumour growth
7. UT Southwestern researchers define regions of human genes highly prone to mutation
8. More dialysis, highly permeable artificial kidney may not aid some, UT Southwestern researcher finds
9. With help from the Office of Naval Research, a right whale pied "Piper" shows the way to recovery for this highly endangered species
10. A highly conserved mechanism used during the development of zebrafish and fruitfly eyes points to a common evolutionary origin of animal eyes
11. Seafloor off Mid-Atlantic coast highly charged with gas

Post Your Comments:

(Date:5/21/2020)... (PRWEB) , ... May 20, 2020 , ... ... and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health ... & Gene Therapy, will be presenting at the ISCT 2020 Paris Virtual conference, ...
(Date:5/15/2020)... FREDERICK, Md. (PRWEB) , ... May 15, 2020 , ... ... a boutique intellectual property law firm based in Frederick, Maryland and Tysons Corner, Virginia, ... the field of biotechnology and a another in the field of chemistry. The firm ...
(Date:5/14/2020)... ALPHARETTA, Ga. (PRWEB) , ... May 14, 2020 ... ... ), a job board for medical sales representatives, found the 2019 average medical ... encouraging 2020 findings risk being shadowed by uncertainties amid the COVID-19 global crisis. ...
Breaking Biology News(10 mins):
(Date:5/15/2020)... (PRWEB) , ... May 14, 2020 , ... This new ... unforeseen and the most pressing questions answered quickly as the need arises. Lachman’s OnCall ... offering valuable advice at affordable rates. , Lachman OnCall™ SMEs are available normal ...
(Date:5/14/2020)... ... May 13, 2020 , ... Early stages of ... little or no information on the drug’s mechanism of action (MOA). Gene expression ... by measuring the activity of molecular pathways. This information can complement phenotypic readouts ...
(Date:5/1/2020)... ... April 30, 2020 , ... ... today, honoring the businesses, policies, projects, and concepts that are actively engaged and ... for living cells, which has taken out the top prize in the Experimental ...
(Date:4/22/2020)... (PRWEB) , ... April 21, 2020 , ... ... continue their work through COVID-19. Many clinical trial teams are working remotely and ... Ripple Science wants to help researchers continue their research during this uncertain time ...
Breaking Biology Technology:
Cached News: